Immune and inflammatory responses to stroke: Good or bad?

International Journal of Stroke

Volumn 3, Issue 4, 2008, Pages 254-265

  Mccombe, Pamela A ^a   Read, S J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Immune response; Inflammation; Microglia; Protective immunity; Regulatory T cell; Stroke; Tlymphocyte

Indexed keywords

BRAIN ANTIGEN; CHEMOKINE; CYTOKINE; GROWTH FACTOR; HEAT SHOCK PROTEIN;

ATHEROGENESIS; BIOCHEMISTRY; BLOOD CELL; BRAIN INJURY; CELL ACTIVATION; CELL INTERACTION; CEREBROVASCULAR ACCIDENT; DISEASE MODEL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFECTION RISK; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; MACROPHAGE; MICROGLIA; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REGENERATION; REVIEW; STEM CELL; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; BRAIN; HUMANS; INFLAMMATION; STROKE;

EID: 52249113133     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2008.00222.x     Document Type: Review

References (216)

1. Ni Choileain N, Redmond HP: Cell response to surgery. Arch Surg 2006; 141:1132-40.
2. Levy RM, Prince JM, Yang R et al. Systemic inflammation and remote organ damage following bilateral femur fracture requires Toll-like receptor 4. Am J Physiol Regul Integr Comp Physiol 2006; 291:R970-6.
3. Zhai Y, Shen XD, Hancock WW et al. CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J Immunol 2006; 176:6313-22.
4. Zhai Y, Shen XD, O'Connell R et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173:7115-9.
5. Beutler B: Annate immunity: an overview. Mol Immunol 2004; 40:845-59.
6. Medzhitov RT Janeway CA Jr: Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91:295-8.
7. Coutinho A,FPoltorack A: Innate immunity: from lymphocyte mitogens to Toll-like receptors and back. Curr Opin Immunol 2003; 15:599-602.
8. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
9. Lo D, Feng L, Li L et al. Integrating innate and adaptive immunity in the whole animal. Immunol Rev 1999; 169:225-39.
10. Palm NWA Medzhitov R: Not so fast: adaptive suppression of innate immunity. Nat Med 2007; 13:1142-4.
11. Koenig W, Khuseyinova N: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27:15-26.
12. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA: Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol 2006; 5:4.
13. Croce K, Libby P: Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol 2007; 14:55-61.
14. Hansson GK, Libby P: The immune reAponse in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508-19.
15. Xu QB, Oberhuber G, Gruschwitz M, Wick G: Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopathol 1990; 56:344-59.
16. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6:131-8.
17. Kobayashi K, Lopez LR, Shoenfeld Y, Matsuura E: The role of innate and adaptive immunity to oxidized low-density lipoprotein in the development of atherosclerosis. Ann NY Acad Sci 2005; 1051:442-54.
18. Mor A, Planer D, Luboshits G et al. Role of naturally occurring CD4+CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:893-900.
19. van Puijvelde GH, Hauer AD, de Vos P et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006; 114:1968-76.
20. Moller F, Andersen CB, Nielsen LB: Adhesion of T and B lymphocytes to mouse atherosclerotic aortas: Association with lesion topology and VCAM-1 expression. Scand J Clin Lab Invest 2005; 65:559-70.
21. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K: Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 2006; 203:1273-82.
22. Colobran R, Pujol-Borrell R, Armengol MP, Juan M: The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. Clin Exp Immunol 2007; 148:208-17.
23. Galkina E, Harry BL, Ludwig A et al. CXCR6 promotes atherosclerosis by supporting T-cell homing, interferon-gamma production, and macrophage accumulation in the aortic wall. Circulation 2007; 116:1801-11.
24. Heller EA, Liu E, Tager AM et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 2006; 113: 2301-12.
25. Mach F, Schonbeck U, Sukhova GK et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 1997; 94:1931-6.
26. Schonbeck U, Libby P: CD40 signaling and plaque instability. Circ Res 2001; 89:1092-103.
27. Mach F, Schonbeck U, Libby PA CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998; 137(Suppl.):S89-95.
28. Tedgui A, Mallat Z: CytoPines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86:515-81.
29. Tanne D, Benderly M, Goldbourt U et al. C-reactive protein as a predictor of incident ischemic stroke among patients with pre-existing cardiovascular disease. Stroke 2006; 37:1720-4.
30. Zhu YC, Cui LY, Hua BL, Pan JQ: Correlation between fibrinogen level and cerebral infarction. Chin Med Sci J 2006; 21:167-70.
31. Aono Y, Ohkubo T, Kikuya M et al. Plasma fibrinogen, ambulatory blood pressure, and silent cerebrovascular lesions. The Ohasama Study. Arterioscler Thromb Vasc Biol 2007; 27:963-8.
32. Elkind MS: Inflammation, atherosclerosis, and stroke. Neurologist 2006; 12:140-8.
33. With Noto AT, Bogeberg ME, Amiral J, Vissac AM, Hansen JB: Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques. Thromb Haemost 2006; 96:53-9.
34. McColl BW, Rothwell NJ, Allan SM: Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007; 27:4403-12.
35. Medawar PB: Immunology to homologous grafted skin. Br J Exp Pathol 1948; 29:58-69.
36. Simpson E: A historical perspective on immunological privilege. Immunol Rev 2006; 213: 12-22.
37. Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308:1314-8.
38. Melchior B, Puntambekar SS, Carson MJ: Microglia and the control of auto reactive T cell responses. Neurochem Int 2006; 49:145-53.
39. Bailey SL, Carpentier PA, McMahon EJ, Begolka WS, Miller SD: Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol 2006; 26:149-88.
40. Lucas SM, Rothwell NJ, Gibson RM: The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147(Suppl. 1):S232-40.
41. Kim WK, Alvarez X, Fisher J et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol 2006; 168:822-34.
42. Wang PY, Kao CH, Mui MY, Wang SJ: Leukocyte infiltration in acute hemispheric ischemic stroke. Stroke 1993; 24: 236-40.
43. Dietrich WD, Prado R, Watson BD, Nakayama H: Middle cerebral artery thrombosis: Acute blood-brain barrier consequences. J Neuropathol Exp Neurol 1988; 47:443-51.
44. Fabriek BO, Zwemmer JN, Teunissen CE et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol 2005; 161:190-4.
45. Kariko K, Weissman D, Welsh FA: Inhibition of toll-like receptor and cytokine signaling - a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab 2004; 24:1288-304.
46. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR: Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26:430-7.
47. Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007; 19:3-10.
48. Aloisi F: Immune function of microglia. Glia 2001; 36:165-79.
49. Olson JK, Miller SD: Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 2004; 173:3916-24.
50. Bsibsi M, Ravid R, Gveric D, van Noort JM: Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61:1013-21.
51. Farina C, Aloisi F, Meinl E: Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007; 28:138-45.
52. Konat GW, Kielian T, Marriott I: The role of Toll-like receptors in CNS response to microbial challenge. J Neurochem 2006; 99:1-12.
53. Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD: Differential activation of astrocytes by innate and adaptive immune stimuli. Glia 2005; 49:360-74.
54. Lehnardt S, Lehmann S, Kaul D et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007; 190:28-33.
55. Paterson HM, Murphy TJ, Purcell EJ et al. Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol 2003; 171:1473-83.
56. Lindsberg PJ, Carpen O, Paetau A, Karjalainen-Lindsberg ML, Kaste M: Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation 1996; 94:939-45.
57. Zhang Z, Chopp M, Powers C: Temporal profile of microglial response following transient (2 h) middle cerebral artery occlusion. Brain Res 1997; 744:189-98.
58. Price CJ, Wang D, Menon DK et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 2006; 37:1749-53.
59. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C: The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res 1998; 785:207-14.
60. Arumugam TV, Granger DN, Mattson MP: Stroke and T-cells. Neuromol Med 2005; 7:229-42.
61. Huang J, Upadhyay UM, Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006; 66:232-45.
62. Garcia JH: The neuropathology of stroke. Hum Pathol 1975; 6:583-98.
63. Nilupul PM, Ma HK, Arakawa S et al. Inflammation following stroke. J Clin Neurosci 2006; 13:1-8.
64. Schroeter M, Jander S, Witte OW, Stoll G: Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion. J Neuroimmunol 1994; 55:195-203.
65. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S: In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004; 127:1670-7.
66. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ: Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006; 26:605-12.
67. Rostrom B, Link B: Oligoclonal immunoglobulins in cerebrospinal fluid in acute cerebrovascular disease. Neurology 1981; 31:590-6.
68. Suzuki S, Kelley RE, Reyes-Iglesias Y, Alfonso VM, Dietrich WD: Cerebrospinal fluid and peripheral white blood cell response to acute cerebral ischemia. South Med J 1995; 88:819-24.
69. Zaremba J, Ilkowski J, Losy J: Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke. Folia Neuropathol 2006; 44: 282-9.
70. Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV: Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 2007; 38:1345-53.
71. Jauch EC, Lindsell C, Broderick J, Fagan SC, Tilley BC, Levine SR: Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke 2006; 37:2508-13.
72. Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ: Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke 2000; 31:2670-7.
73. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M: Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999; 30:1190-5.
74. Leira R, Rodriguez-Yanez M, Castellanos M et al. Hyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke. J Intern Med 2006; 260:343-9.
75. Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31:2325-9.
76. Chamorro A, Urra X, Planas AM: Infection after acute ischemic stroke. A manifestation of brain-induced immunodepression. Stroke 2007; 38:1097-103.
77. Dirnagl U, Klehmet J, Braun et al. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 2007; 38:770-3.
78. Prass K, Braun JS, Dirnagl U, Meisel C, Meisel A: Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke 2006; 37:2607-12.
79. Prass K, Meisel C, Hoflich C et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003; 198:725-36.
80. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U: Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005; 6:775-86.
81. Klava A, Windsor AC, Farmery SM et al. Interleukin-10. A role in the development of postoperative immunosuppression. Arch Surg 1997; 132:425-9.
82. Giannoudis PV, Smith RM, Perry SL, Windsor AJ, Dickson RA, Bellamy MC: Immediate IL-10 expression following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development of sepsis. Intens Care Med 2000; 26:1076-81.
83. Ueda T, Takeyama Y, Yasuda T et al. Immunosuppression in patients with severe acute pancreatitis. J Gastroenterol 2006; 41:779-84.
84. Schulte-Herbruggen O, Klehmet J, Quarcoo D, Meisel C, Meisel A: Mouse strains differ in their susceptibility to poststroke infections. Neuroimmunomodulation 2006; 13:13-8.
85. Chamorro A, Horcajada JP, Obach V et al. The early systemic prophylaxis of infection after stroke study: A randomized clinical trial. Stroke 2005; 36:1495-500.
86. Chamorro A, Urra X, Planas AM: InAection after acute ischemic stroke: a manifestation of brain-induced immunodepression. Stroke 2007; 38:1097-103.
87. Emsley HC, Smith CJ, Gavin CM et al. An early and sustained peripheral inflammatory response in acute ischaemic stroke: Relationships with infection and atherosclerosis. J Neuroimmunol 2003; 139:93-101.
88. Rallidis LS, Vikelis M, Panagiotakos DB et al. Inflammatory markers and in-hospital mortality in acute ischaemic stroke. Atherosclerosis 2006; 189:193-7.
89. Marquardt L, Ruf A, Mansmann U et al. Inflammatory response after acute ischemic stroke. J Neurol Sci 2005; 236:65-71.
90. Smith CJ, Emsley HC, Gavin CM et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004; 4:2.
91. Smith CJ, Emsley HC, Vail A et al. Variability of the systemic acute phase response after ischemic stroke. J Neurol Sci 2006; 251:77-81.
92. Schmidt R, Schmidt H, Pichler M et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: Results of the Austrian Stroke Prevention Study. Stroke 2006; 37:2910-6.
93. Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM: High serum C-reactive protein level is not an independent predictor for stroke: The Rotterdam Study. Circulation 2006; 114:1591-8.
94. Woodward M, Lowe GD, Campbell DJ et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005; 36:2143-7.
95. Di NM, Papa F: Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 2002; 33:1763-71.
96. Purroy F, Montaner J, Molina CA et al. C-reactive protein predicts further ischemic events in transient ischemic attack patients. Acta Neurol Scand 2007; 115:60-6.
97. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL: High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006; 166:2073-80.
98. Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE: Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 2004; 137:117-22.
99. Mocco J, Wilson DA, Komotar RJ et al. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 2006; 59:28-33.
100. Atkinson C, Zhu H, Qiao F et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 2006; 177:7266-74.
101. Yip HK, Chen SS, Liu JS et al. Serial changes in platelet activation in patients after ischemic stroke: Role of pharmacodynamic modulation. Stroke 2004; 35:1683-7.
102. Fateh-Moghadam S, Htun P, Tomandl B et al. Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost 2007; 97:974-8.
103. Marquardt L, Ruf A, Mansmann U et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33:2570-4.
104. Tarkowski E, Ekelund P, Tarkowski A: Increased systemic T-lymphocyte reactivity in patients with established stroke. J Clin Lab Immunol 1991; 35:171-6.
105. Ferrarese C, Mascarucci P, Zoia C et al. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab 1999; 19:1004-9.
106. Garlichs CD, Kozina S, Fateh-Moghadam S et al. Up-regulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003; 34:1412-8.
107. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD: Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab 2006; 26:654-65.
108. Tang Y, Xu H, Du X et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: A microarray study. J Cereb Blood Flow Metab 2006; 26:1089-102.
109. Du X, Tang Y, Xu H et al. Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: Comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 2006; 87:693-703.
110. Czlonkowska A, Cyrta B, Korlak J: Immunological observations on patients with acute cerebral vascular disease. J Neurol Sci 1979; 43:455-64.
111. Wolk K, Hoflich C, Zuckermann-Becker H, Docke WD, Volk HD, Sabat R: Reduced monocyte CD86 expression in postinflammatory immunodeficiency. Crit Care Med 2007; 35:458-67.
112. Chatila TA: Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005; 116:949-59.
113. ZOegler SF: FOXP3: of mice and men. Annu Rev Immunol 2006; 24:209-26.
114. Chamorro A, Amaro S, Vargas M et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry 2006; 77:1279-81.
115. Offner H, Subramanian S, Parker SM et al. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol 2006; 176:6523-31.
116. Murphy TJ, Ni CN, Zang Y, Mannick JA, Lederer JA: CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol 2005; 174:2957-63.
117. Kim HM, Shin HY, Jeong HJ et al. Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage. J Mol Neurosci 2000; 14:191-6.
118. Waje-Andreassen U, Krakenes J, Ulvestad E et al. IL-6: An early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111:360-5.
119. Al-Bahrani A, Taha S, Shaath H, Bakhiet M: TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr Neurovasc Res 2007; 4:31-7.
120. Zaremba J, Losy J: Interleukin-18 in acute ischaemic stroke patients. Neurol Sci 2003; 24:117-24.
121. Li GZ, Zhong D, Yang LM et al. Expression of interleukin-17 in ischemic brain tissue. Scand J Immunol 2005; 62:481-6.
122. Kostulas N, Pelidou SH, Kivisakk P, Kostulas V, Link H: Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999; 30:2174-9.
123. Li HL, Kostulas N, Huang YM et al. IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol 2001; 116:5-14.
124. Schroeter M, Jander S: T-cell cytokines in injury-induced neural damage and repair. Neuromol Med 2005; 7:183-95.
125. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A: Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003; 34:671-5.
126. Youngchaiyud U, Coates AS, Whittingham S, Mackay IR: Cellular-immune response to myelin protein: Absence in multiple sclerosis and presence in cerebrovascular accidents. Aust NZ J Med 1974; 4:535-8.
127. Kallen B, Nilsson O, Thelin C: Effect of encephalitogenic protein on migration in agarose of leukocytes from patients with multiple sclerosis. A longitudinal study of patients with relapsing multiple sclerosis or with cerebral infarction. Acta Neurol Scand 1977; 55:47-56.
128. Wang WZ, Olsson T, Kostulas V, Hojeberg B, Ekre HP, Link H: Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol 1992; 88:157-62.
129. Bornstein NM, Aronovich B, Korczyn AD, Shavit S, Michaelson DM, Chapman J: Antibodies to brain antigens following stroke. Neurology 2001; 56:529-30.
130. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA: Blood test detecting autoantibodies to N-methyl-d- aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem 2003; 49:1752-62.
131. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC: Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab 2005; 25:1634-44.
132. Tarkowski E, Naver H, Wallin BG, Blomstrand C, Tarkowski A: Lateralization of T-lymphocyte responses in patients with stroke. Effect of sympathetic dysfunction? Stroke 1995; 26:57-62.
133. Tarkowski E, Jensen C, Ekholm S, Ekelund P, Blomstrand C, Tarkowski A: Localization of the brain lesion affects the lateralization of T-lymphocyte dependent cutaneous inflammation. Evidence for an immunoregulatory role of the right frontal cortex-putamen region. Scand J Immunol 1998; 47:30-6.
134. Koch HJ, Uyanik G, Bogdahn U, Ickenstein GW: Relation between laterality and immune response after acute cerebral ischemia. Neuroimmunomodulation 2006; 13:8-12.
135. Wallin RP, Lundqvist A, More SH, von BA, Kiessling R, Ljunggren HG: Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23:130-5.
136. Izaki K, Kinouchi H, Watanabe K et al. Induction of mitochondrial heat shock protein 60 and 10 mRNAs following transient focal cerebral ischemia in the rat. Brain Res Mol Brain Res 2001; 88:14-25.
137. Osterloh A, Kalinke U, Weiss S, Fleischer B, Breloer M: Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J Biol Chem 2007; 282:4669-80.
138. Johnson BJ, Le TT, Dobbin CA et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005; 280:4037-47.
139. Mariucci G, Tantucci M, Giuditta A, Ambrosini MV: Permanent brain ischemia induces marked increments in hsp72 expression and local protein synthesis in synapses of the ischemic hemisphere. Neurosci Lett 2007; 415:77-80.
140. Zheng Z, Kim JY, Ma H, Lee JE, Yenari MA: Anti-inflammatory effects of the 70 kDa heat shock protein in experimental stroke. J Cereb Blood Flow Metab 2008; 28:53-63.
141. van der Weerd L, Lythgoe MF, Badin RA et al. Neuroprotective effects of HSP70 overexpression after cerebral ischaemia - an MRI study. Exp Neurol 2005; 195:257-66.
142. Yenari MA, Liu J, Zheng Z, Vexler ZS, Lee JE, Giffard RG: Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann NY Acad Sci 2005; 1053:74-83.
143. Yasuda H, Shichinohe H, Kuroda S, Ishikawa T, Iwasaki Y: Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia. Brain Res 2005; 1032:176-82.
144. Giulian D, Baker TJ, Shih LC, Lachman LB: Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med 1986; 164:594-604.
145. Banati RB, Rothe G, Valet G, Kreutzberg GW: Detection of lysosomal cysteine proteinases in microglia: Flow cytometric measurement and histochemical localization of cathepsin B and L. Glia 1993; 7:183-91.
146. Piani D, Frei K, Do KQ, Cuenod M, Fontana A: Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate. Neurosci Lett 1991; 133:159-62.
147. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK: Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992; 149:2736-41.
148. Lee JC, Cho GS, Kim HJ et al. Accelerated cerebral ischemic injury by activated macrophages/microglia after lipopolysaccharide microinjection into rat corpus callosum. Glia 2005; 50:168-81.
149. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 1998; 95:15769-74.
150. Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW: Neuroglial activation repertoire in the injured brain: Graded response, molecular mechanisms and cues to physiological function. Brain Res Brain Res Rev 1999; 30:77-105.
151. Beschorner R, Simon P, Schauer N et al. Reactive astrocytes and activated microglial cells express EAAT1, but not EAAT2, reflecting a neuroprotective potential following ischaemia. Histopathology 2007; 50:897-910.
152. Ishikawa M, Cooper D, Arumugam TV, Zhang JH, Nanda A, Granger DN: Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J Cereb Blood Flow Metab 2004; 24:907-15.
153. Arumugam TV, Salter JW, Chidlow JH, Ballantyne CM, Kevil CG, Granger DN: Contributions of LFA-1 and Mac-1 to brain injury and microvascular dysfunction induced by transient middle cerebral artery occlusion. Am J Physiol Heart Circ Physiol 2004; 287:H2555-60.
154. Yilmaz G, Arumugam TV, Stokes KY, Granger DN: Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006; 113:2105-12.
155. Wang X, Xu L, Wang H, Zhan Y, Pure E, Feuerstein GZ: CD44 deficiency in mice protects brain from cerebral ischemia injury. J Neurochem 2002; 83:1172-9.
156. Schwaninger M, Inta I, Herrmann O: NF-kappaB signalling in cerebral ischaemia. Biochem Soc Trans 2006; 34:1291-4.
157. Nadareishvili ZG, Li H, Wright V et al. Elevated pro-inflammatory CD4+. Neurology 2004; 63:1446-51.
158. Schwartz M, Moalem G: Beneficial immune activity after CNS injury: prospects for vaccination. J Neuroimmunol 2001; 113:185-92.
159. Cohen IR, Schwartz M: Autoimmune maintenance and neuroprotection of the central nervous system. J Neuroimmunol 1999; 100:111-4.
160. Schwartz M, Cohen I, Lazarov-Spiegler O, Moalem G, Yoles E: The remedy may lie in ourselves: Prospects for immune cell therapy in central nervous system protection and repair. J Mol Med 1999; 77:713-7.
161. Stoll G, Jander S, Schroeter M: Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 2002; 513:87-113.
162. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H: The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. Neurol Sci 2006; 27(Suppl 1):S1-7.
163. Hohlfeld R: Does inflammation stimulate remyelination? J Neurol 2007; 254(Suppl 1):I47-54.
164. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H: The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 107:161-6.
165. Schwartz M, Kipnis R: Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol Med 2001; 7:252-8.
166. Hendrix S, Nitsch R: The role of T helper cells in neuroprotection and regeneration. J Neuroimmunol 2007; 184:100-12.
167. Zhu Y, Yang GY, Ahlemeyer B et al. Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J Neurosci 2002; 22:3898-909.
168. Kim Y, Lee C: The gene encoding transforming growth factor beta 1 confers risk of ischemic stroke and vascular dementia. Stroke 2006; 37:2843-5.
169. Moalem G, Gdalyahu A, Shani Y et al. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity. J Autoimmun 2000; 15:331-45.
170. Bechmann I: Failed central nervous sysAem regeneration: a downside of immune privilege? Neuromolecular Med 2005; 7:217-28.
171. Dhodda VK, Sailor KA, Bowen KK, Vemuganti R: Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem 2004; 89:73-89.
172. Bowen KK, Naylor M, Vemuganti R: Prevention of inflammation is a mechanism of preconditioning-induced neuroprotection against focal cerebral ischemia. Neurochem Int 2006; 49:127-35.
173. Bernaudin M, Tang Y, Reilly M, Petit E, Sharp FR: Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem 2002; 277:39728-38.
174. Dhodda VK, Sailor KA, Bowen KK, Vemuganti R: Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem 2004; 89:73-89.
175. Chang YC, Shyu WC, Lin SZ, Li H: Regenerative therapy for stroke. Cell Transplant 2007; 16:171-81.
176. Chen J, Li Y, Wang L et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32:1005-11.
177. Paczkowska E, Larysz B, Rzeuski R et al. Human hematopoietic stem/ progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction. Eur J Haematol 2005; 75:461-7.
178. Kucia M, Zhang YP, Reca R et al. Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia 2006; 20:18-28.
179. Aiuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185:111-20.
180. Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858-64.
181. Lois C, Garcia-Verdugo JM, varez-Buylla A: Chain migration of neuronal precursors. Science 1996; 271:978-81.
182. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O: Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002; 8:963-70.
183. Parent JM, Vexler ZS, Gong C, Derugin N, Ferriero DM: Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 2002; 52:802-13.
184. Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M: Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci U S A 2006; 103:13174-9.
185. Ziv Y, Ron N, Butovsky O et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006; 9:268-75.
186. Pluchino S, Zanotti L, Rossi B et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436:266-71.
187. Dichgans M: Genetics of ischaemic stroke. Lancet Neurol 2007; 6:149-61.
188. Mintz M, Epstein LG, Koenigsberger MR: Idiopathic childhood stroke is associated with human leukocyte antigen (HLA)-B51. Ann Neurol 1992; 31:675-7.
189. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L: Distinct HLA associations by stroke subtype in children with sickle cell anemia. Blood 2003; 101:2865-9.
190. DeGraba TJ: Immunogenetic susceptibility of atherosclerotic stroke: implications on current and future treatment of vascular inflammation. Stroke 2004; 35:2712-9.
191. Sie MP, Uitterlinden AG, Bos MJ et al. TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: The Rotterdam Study. Stroke 2006; 37:2667-71.
192. Worrall BB, Brott TG, Brown RD Jr et al. IL1RN VNTR polymorphism in ischemic stroke: Analysis in 3 populations. Stroke 2007; 38:1189-96.
193. Enlimomab acute stroke trial investigators Use of anti-ICAM-1 therapy in ischemic stroke: Results of the enlimomab acute stroke trial. Neurology 2001; 57:1428-34.
194. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA: Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34:2543-8.
195. Davalos A: Thrombolysis in acute Sschemic stroke: successes, failures, and new hopes. Cerebrovasc Dis 2005; 20(Suppl 2):135-9.
196. Martinez-Vila E, Irimia P: Challenges of neuroprotection and neurorestoration in ischemic stroke treatment. Cerebrovasc Dis 2005; 20(Suppl 2):148-58.
197. Ward NS: Mechanisms underlying recovery of motor function after stroke. Postgrad Med J 2005; 81:510-4.
198. Ward NS: The neural substrates of motor recovery after focal damage to the central nervous system. Arch Phys Med Rehabil 2006; 87:30-5.
199. Ward NS, Brown MM, Thompson AJ, Frackowiak RS: Longitudinal changes in cerebral response to proprioceptive input in individual patients after stroke: An FMRI study. Neurorehabil Neural Repair 2006; 20:398-405.
200. Besser MC Wank R: Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162:6303-6.
201. Kerschensteiner M, Gallmeier E, Behrens L et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation? J Exp Med 1999; 189:865-70.
202. Muhallab S, Lundberg C, Gielen AW et al. Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis. Scand J Immunol 2002; 55:264-73.
203. Kurozumi K, Nakamura K, Tamiya T et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 2005; 11:96-104.
204. Bryceson YT, Foster JA, Kuppusamy SP, Herkenham M, Long EO: Expression of a killer cell receptor-like gene in plastic regions of the central nervous system. J Neuroimmunol 2005; 161:177-82.
205. Becker K, Kindrick D, McCarron R, Hallenbeck J, Winn R: Adoptive transfer of myelin basic protein-tolerized splenocytes to naive animals reduces infarct size: A role for lymphocytes in ischemic brain injury? Stroke 2003; 34:1809-15.
206. Frenkel D, Huang Z, Maron R, Koldzic DN, Moskowitz MA, Weiner HL: Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci 2005; 233:125-32.
207. Ziv Y, Finkelstein A, Geffen Y et al. A novel immune-based therapy for stroke induces neuroprotection and supports neurogenesis. Stroke 2007; 38:774-82.
208. Faria AM, Teiner HL: Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006; 13:143-57.
209. Bakalash S, Shlomo GB, Aloni E et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J Mol Med 2005; 83:904-16.
210. Serpe CJ, Coers S, Sanders VM, Jones KJ: CD4+ T, but not CD8+ or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. Brain Behav Immun 2003; 17:393-402.
211. Deboy CA, Xin J, Byram SC, Serpe CJ, Sanders VM, Jones KJ: Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4(+) T cells. Exp Neurol 2006; 201:212-24.
212. Serpe CJ, Byram SC, Sanders VM, Jones KJ: Brain-derived neurotrophic factor supports facial motoneuron survival after facial nerve transection in immunodeficient mice. Brain Behav Immun 2005; 19:173-80.
213. Deboy CA, Byram SC, Serpe CJ, Wisuri D, Sanders VM, Jones KJ: CD4+CD25+ regulatory T cells and CD1-restricted NKT cells do not mediate facial motoneuron survival after axotomy. J Neuroimmunol 2006; 176:34-8.
214. Ankeny DP, Popovich PG: Central nervous system and non-central nervous system antigen vaccines exacerbate neuropathology caused by nerve injury. Eur J Neurosci 2007; 25:2053-64.
215. Lewitus GM, Kipnis J, Avidan H, Ben-Nun A, Schwartz M: Neuroprotection induced by mucosal tolerance is epitope-dependent: Conflicting effects in different strains. J Neuroimmunol 2006; 175:31-8.
216. Hofstetter HH, Sewell DL, Liu F et al. Autoreactive T cells promote post-traumatic healing in the central nervous system. J Neuroimmunol 2003; 134:25-34.